Oral Low-Dose Ferric Citrate Is a Useful Iron Source for Hyperphosphatemic Hemodialysis Patients: A Case Series.
Blood Purif
; 43(1-3): 97-100, 2017.
Article
em En
| MEDLINE
| ID: mdl-27951582
ABSTRACT
BACKGROUND:
Randomized trials have demonstrated that a phosphate binder ferric citrate (FeC) increases iron parameters in comparison with other phosphate binders, but the doses for FeC to improve iron stores safely have not been clarified.METHODS:
We examined changes of iron parameters and blood hemoglobin (Hb) in 7 iron-deficient hemodialysis (HD) patients taking FeC 750 mg/day as a phosphate binder.RESULTS:
The median serum transferrin saturation and ferritin increased from 13% (interquartile range (IQR) 7-18) to 28% (IQR 22-31; p = 0.010) and from 17 ng/ml (IQR 11-60) to 106 ng/ml (IQR 58-176; p = 0.015) by 2 and 3 months respectively. With the persistence of these levels thereafter, the FeC administration reduced the usage of erythropoiesis-stimulating agents while maintaining adequate blood Hb levels.CONCLUSION:
Oral FeC 750 mg/day improves iron stores without inducing iron overload in hyperphosphatemic HD patients.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Compostos Férricos
/
Diálise Renal
/
Hiperfosfatemia
/
Ferro
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article